Shijiazhuang Yiling Pharmaceutical Co., Ltd. Share Price
Equities
002603
CNE1000015S0
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.95 CNY | -0.29% |
|
+3.35% | -0.70% |
| 04/03 | Yiling Pharmaceutical Unit Gets Nod to Market Anti-Tumor Drug | MT |
| 23/01 | Yiling Pharma's Unit Gets Nod for Registration of Aniline Profen Injection | MT |
| Capitalization | 2.83TCr 412.3Cr 357.98Cr 323.97Cr 308.84Cr 562.23Cr 38TCr 582.5Cr 3.85TCr 1.53TCr 18TCr 1.55TCr 1.51TCr 66TCr | P/E ratio 2025 * |
23.5x | P/E ratio 2026 * | 19.2x |
|---|---|---|---|---|---|
| Enterprise value | 2.79TCr 406.11Cr 352.6Cr 319.1Cr 304.21Cr 553.79Cr 37TCr 573.76Cr 3.8TCr 1.5TCr 18TCr 1.52TCr 1.49TCr 65TCr | EV / Sales 2025 * |
2.76x | EV / Sales 2026 * | 2.41x |
| Free-Float |
42.61% | Yield 2025 * |
1.53% | Yield 2026 * | 1.77% |
| 1 day | -0.29% | ||
| 1 week | +3.35% | ||
| Current month | -3.03% | ||
| 1 month | -4.35% | ||
| 3 months | -4.02% | ||
| 6 months | -2.75% | ||
| Current year | -0.70% |
| 1 week | 16.31 |  | 17.12 |
| 1 month | 16.28 | | 17.84 |
| Current year | 16.28 | | 20.26 |
| 1 year | 12.41 | | 21.58 |
| 3 years | 12.41 | | 33.29 |
| 5 years | 12.41 | | 53.96 |
| 10 years | 7.08 | | 53.96 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiang Jun Wu
CEO | Chief Executive Officer | 51 | 01/04/2013 |
Chen Guang Li
DFI | Director of Finance/CFO | 53 | 24/04/2018 |
Qiu Lian Zhang
PRN | Corporate Officer/Principal | 56 | 16/01/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Yi Ling Wu
CHM | Chairman | 77 | 31/08/2012 |
Xiang Jun Wu
BRD | Director/Board Member | 51 | 31/08/2010 |
Chen Guang Li
BRD | Director/Board Member | 53 | 17/05/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.29% | +3.35% | +20.04% | -40.57% | 413.59Cr | |
| -0.50% | +1.21% | -17.62% | -38.54% | 603.53Cr | |
| +0.02% | -0.25% | -9.58% | +11.11% | 490.23Cr | |
| -1.25% | +2.47% | +35.10% | +18.23% | 416.74Cr | |
| -1.52% | -3.73% | -4.59% | -7.86% | 362.65Cr | |
| -0.42% | +3.33% | -5.12% | +4.08% | 311.96Cr | |
| +0.12% | +3.95% | +11.95% | -13.63% | 258.61Cr | |
| -0.65% | -4.75% | +6.63% | -1.54% | 202.58Cr | |
| +1.92% | +2.73% | +4.71% | +42.60% | 175.33Cr | |
| -1.33% | +2.64% | +4.62% | +32.09% | 166.76Cr | |
| Average | -0.39% | -0.31% | +4.62% | +0.60% | 340.2Cr | |
| Weighted average by Cap. | -0.47% | -0.31% | +3.05% | -5.76% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.01TCr 146.95Cr 127.59Cr 115.46Cr 110.08Cr 200.39Cr 14TCr 207.61Cr 1.37TCr 544.56Cr 6.5TCr 551.39Cr 539.67Cr 23TCr | 1.11TCr 162.14Cr 140.78Cr 127.4Cr 121.46Cr 221.1Cr 15TCr 229.07Cr 1.52TCr 600.87Cr 7.17TCr 608.4Cr 595.46Cr 26TCr |
| Net income | 121Cr 18Cr 15Cr 14Cr 13Cr 24Cr 1.63TCr 25Cr 164.71Cr 65Cr 778.88Cr 66Cr 65Cr 2.81TCr | 148.1Cr 22Cr 19Cr 17Cr 16Cr 29Cr 1.99TCr 30Cr 201.6Cr 80Cr 953.33Cr 81Cr 79Cr 3.43TCr |
| Net Debt | -43Cr -6.19Cr -5.37Cr -4.86Cr -4.64Cr -8.44Cr -571.42Cr -8.74Cr -58Cr -23Cr -273.6Cr -23Cr -23Cr -985.72Cr | -143.51Cr -21Cr -18Cr -16Cr -16Cr -28Cr -1.93TCr -30Cr -195.35Cr -77Cr -923.76Cr -78Cr -77Cr -3.33TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | 16.95 ¥ | -0.29% | 80,86,535 |
| 11/26/11 | 17.00 ¥ | +0.53% | 1,23,79,200 |
| 10/26/10 | 16.91 ¥ | +0.77% | 1,02,10,780 |
| 09/26/09 | 16.78 ¥ | +0.12% | 1,51,87,720 |
| 06/26/06 | 16.76 ¥ | +1.95% | 1,31,98,920 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 002603 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition